Early Cancer Edge Hawkeye Bio focuses on early detection of cancer through measuring cancer-related enzyme activity in asymptomatic individuals, offering a fast, safe, and affordable solution. Sales opportunities exist with adjacent diagnostic markets and clinical laboratories seeking innovative early-detection tools.

Graphene Sensor Platform Recent news indicates development of graphene-based biosensor technology to power next‑gen diagnostic assays, with initial emphasis on lung cancer detection and monitoring. This opens cross‑sell opportunities with pharma/biotech partners and contract research organizations pursuing advanced sensing capabilities.

Strategic Partnerships Collaboration with HydroGraph Clean Power Inc. on medical testing applications signals openness to aerospace/clean‑tech healthcare synergies and potential channel partnerships to co‑develop and commercialize diagnostic workflows.

CLIA Lab Presence Expansion to a CLIA-certified facility in Torrance demonstrates readiness for clinical testing and direct-to-lab or hospital‑side deployment, enabling conversations with laboratories, clinics, and health systems about validation, reimbursement, and scale‑up.

Financial Position Revenue in the low‑to‑mid millions with around nine million in funding suggests a seed‑to‑growth phase with capacity for pilot programs and strategic investments; sales conversations can target early adopters, pilot customers, and grant-funded research projects to de‑risk adoption.